Cover Image
市場調查報告書

頭孢菌素劑的全球市場 - 各世代、給藥途徑、藥物、地理的成長率,趨勢及預測(2018年∼2023年)

Global Cephalosporin Drugs Market - Generation, Route of Administration, Drug, and Geography - Growth, Trends and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 391378
出版日期 內容資訊 英文 112 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
頭孢菌素劑的全球市場 - 各世代、給藥途徑、藥物、地理的成長率,趨勢及預測(2018年∼2023年) Global Cephalosporin Drugs Market - Generation, Route of Administration, Drug, and Geography - Growth, Trends and Forecast (2018 - 2023)
出版日期: 2018年04月01日 內容資訊: 英文 112 Pages
簡介

全球頭孢菌素劑市場,預計從2018年到2023年的預測期間內以約3.5%的年複合成長率成長。頭孢菌素劑,屬於殺菌性β-內醯胺抗生素類,為了防止細菌的增生透過阻礙細胞牆合成。由於人口的增加,經濟發展,醫療費,感染疾病的流行等,預計在預測期間中亞太地區在市場上具優勢。

本報告提供全球頭孢菌素劑市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會及挑戰分析(DROC)

  • 市場成長要素
    • 各種適應症的抗菌藥的需求高漲
    • 企業的聯合使研究開發活動活性化
    • 感染疾病的流行
    • 聯合治療的使用增加
  • 市場阻礙因素
    • 嚴格的法規指南
    • 弱的開發平台分子
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各世代
    • 第1代
    • 第2代
    • 第3代
    • 第4代
    • 第5代
  • 各給藥途徑
    • 口服
    • 注射劑
  • 藥物的各類型
    • 品牌
    • 非專利
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Abbott
  • Astellas Pharma Inc.
  • Baxter International
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceuticals 等

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52448

The global cephalosporin drugs market is expected to register a CAGR of around 3.5% during the forecast period, 2018 to 2023. Cephalosporin drugs belong to the class of bactericidal beta-lactam antibiotics. They act by inhibiting the cell wall synthesis to prevent the growth of bacteria. With large population base, rising economies, healthcare expenditure, and prevalence of infectious diseases, the Asia-Pacific region is expected to dominate the market during the forecast period.

Rising R&D Activities through Company Collaborations

With rising investment cost of R&D and cost of further manufacture of drugs, several large-, medium- and small-sized biotech and pharma companies come together for a collaborative partnership with larger firms. Usually, small companies have good R&D facilities but do not have sufficient capital for conducting global, multicenter, and large-scale clinical trials. Most of them out-license their products after early clinical development phase. For example, in the past, GlaxoSmithKline collaborated with Anacor Pharmaceuticals for development and commercialization of antibacterial and anti-viral drugs. Recently, Shionogi & Co. Ltd collaborated with F. Hoffmann-La Roche Ltd for a siderophore cephalosporin development. This is one of the major factors for the growth of the cephalosporin drugs market.

Other factors, such as rising demand of anti-microbial for various diseases, rising prevalence of infectious diseases and use of combination therapies are some of the primary factors for the growth of this market.

Stringent Regulatory Guidelines

There are several regulatory aspects involved in the pharmaceutical industries, along with the complexity of the market, which affects their growth in the market. Several companies are not able to pass through the stringent bioequivalence testing for checking the therapeutic potential and toxicity levels. In the past decade, several APAC countries tightened their monitoring and inspection of imported antibiotics with more stringent requirements for their testing, such as Japan pharmaceutical and Medical Devices Agency and Korean FDA. Another factor is the low number of molecules in the pipeline, which is hindering the growth of the cephalosporin drugs market.

Asia-Pacific to Dominate the Market

The cephalosporin drugs market is segmented by generation, route of administration, drug, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, Middle East & Africa (MEA), and South America.

Asia-Pacific is expected to dominate this market due to high prevalence of infectious diseases, increasing healthcare expenditure, and large population base. Further, the demand for better healthcare infrastructure and government initiatives are expected to help growth in this region. Asia-Pacific is followed by Europe, due to its large base of geriatric population and rising prevalence of infectious diseases in several countries of the region.

Key Developments in the Market

February 2018: AGP Limited aimed to boost the capacity of its cephalosporin plant, to support the increasing demand for its primary products and establish the facilities for neutraceuticals.

February 2018: Allergan is developing combination aztreonam and avibactam for gram-negative infections, which restores the antibacterial activity to cephalosporin.

Major players: ABBOTT, ASTELLAS PHARMA INC., BAXTER INTERNATIONAL, BRISTOL-MYERS SQUIBB COMPANY, GLAXOSMITHKLINE PLC, LUPIN PHARMACEUTICALS, MERCK & CO. INC., PFIZER INC., ROCHE HOLDING AG, AND TEVA PHARMACEUTICALS, amongst others.

Reasons to Purchase the Report

Current and future of the global cephalosporin drugs market outlook in the developed and emerging markets

Analyzing various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 month analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Rising Demand for Anti-microbials in Various Indications
    • 6.1.2 Rising R&D Activities through Company Collaborations
    • 6.1.3 Rising Prevalence of Infectious Diseases
    • 6.1.4 Increasing Use of Combination Therapies
  • 6.2 Market Restraints
    • 6.2.1 Stringent Regulatory Guidelines
    • 6.2.2 Weak Pipeline Molecules
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Generation
    • 7.1.1 First-generation
    • 7.1.2 Second-generation
    • 7.1.3 Third-generation
    • 7.1.4 Fourth-generation
    • 7.1.5 Fifth-generation
  • 7.2 By Route of Adminstration
    • 7.2.1 Oral
    • 7.2.2 Injectables
  • 7.3 By Type of Drug
    • 7.3.1 Branded
    • 7.3.2 Generic
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 United Kingdom
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of the Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbott
  • 9.2 Astellas Pharma Inc.
  • 9.3 Baxter International
  • 9.4 Bristol-Myers Squibb Company
  • 9.5 GlaxoSmithKline PLC
  • 9.6 Lupin Pharmaceuticals
  • 9.7 Merck & Co. Inc.
  • 9.8 Pfizer Inc.
  • 9.9 Roche Holding AG
  • 9.10 Teva Pharmaceuticals
  • 9.11 List Not Exhaustive

10. Future of the Market

Back to Top